BioCentury | Sep 8, 2020
Finance

Algenex raises €7.4 million C round, looks to partner manufacturing platform with COVID-19 vaccine developers

...led by MasterLux with participation from Columbus Life Science Fund II, a fund managed by Columbus Venture Partners...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...NYSE:CTLT) and Viralgen Vector Core, a Spain-based JV between Asklepios Bio Pharmaceutical Inc. (AskBio) and Columbus Venture Partners...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...NYSE:CTLT) and Viralgen Vector Core, a Spain-based JV between Asklepios Bio Pharmaceutical Inc. (AskBio) and Columbus Venture Partners...
BioCentury | Jun 26, 2019
Financial News

Spain’s Sanifit heads to Phase III with €72.2M in new funding

...led by Caixa Capital Risc. The round included two other first-time backers, Spanish venture firms Columbus Venture Partners...
BioCentury | May 24, 2019
Finance

Europe: Some spots hotter than others

...to €250 million ($279 million) -- plus new VC entrants like Alta Life Sciences and Columbus Venture Partners...
BioCentury | Apr 11, 2019
Financial News

TPG, Vida back Asklepios in $235M round

...Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) via Baxalta Inc. and Shire plc. In 2017, Asklepios and Columbus Venture Partners...
BioCentury | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

...Bioscience plc (LSE:ARIX), Lundbeckfonden Ventures, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...
BioCentury | Dec 22, 2017
Financial News

Aura raises $30M series C

...Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...
BioCentury | Dec 21, 2017
Financial News

Aura raises $30M series C

...Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...for rare diseases Foundation for Applied Medical Research Gene / cell therapy; endocrine / metabolic Columbus Venture Partners...
Items per page:
1 - 10 of 12
BioCentury | Sep 8, 2020
Finance

Algenex raises €7.4 million C round, looks to partner manufacturing platform with COVID-19 vaccine developers

...led by MasterLux with participation from Columbus Life Science Fund II, a fund managed by Columbus Venture Partners...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...NYSE:CTLT) and Viralgen Vector Core, a Spain-based JV between Asklepios Bio Pharmaceutical Inc. (AskBio) and Columbus Venture Partners...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...NYSE:CTLT) and Viralgen Vector Core, a Spain-based JV between Asklepios Bio Pharmaceutical Inc. (AskBio) and Columbus Venture Partners...
BioCentury | Jun 26, 2019
Financial News

Spain’s Sanifit heads to Phase III with €72.2M in new funding

...led by Caixa Capital Risc. The round included two other first-time backers, Spanish venture firms Columbus Venture Partners...
BioCentury | May 24, 2019
Finance

Europe: Some spots hotter than others

...to €250 million ($279 million) -- plus new VC entrants like Alta Life Sciences and Columbus Venture Partners...
BioCentury | Apr 11, 2019
Financial News

TPG, Vida back Asklepios in $235M round

...Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) via Baxalta Inc. and Shire plc. In 2017, Asklepios and Columbus Venture Partners...
BioCentury | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

...Bioscience plc (LSE:ARIX), Lundbeckfonden Ventures, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...
BioCentury | Dec 22, 2017
Financial News

Aura raises $30M series C

...Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...
BioCentury | Dec 21, 2017
Financial News

Aura raises $30M series C

...Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...for rare diseases Foundation for Applied Medical Research Gene / cell therapy; endocrine / metabolic Columbus Venture Partners...
Items per page:
1 - 10 of 12